Literature DB >> 3258144

Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia.

P D Walzer1, C K Kim, J M Foy, M J Linke, M T Cushion.   

Abstract

Inhibitors of folic acid synthesis were compared alone and in different combinations in the therapy of pneumocystosis in immunosuppressed rats. Sulfonamides (sulfamethoxazole, sulfadiazine, and sulfadoxine) and sulfones (dapsone) used alone were very active against Pneumocystis carinii, as judged by histologic examination of the lungs and by organism quantitation. Improved efficacy could not be demonstrated by the addition of an inhibitor of dihydrofolate reductase to the regimen. Dihydrofolate reductase inhibitors (trimethoprim, diaveridine, and pyrimethamine) used alone were ineffective against P. carinii. All drugs were well tolerated except pyrimethamine, which caused bone marrow depression; folinic acid ameliorated this adverse reaction but did not interfere with P. carinii treatment. These data have potential clinical implications but need to be interpreted with caution and in light of other systems of P. carinii drug evaluation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258144      PMCID: PMC172106          DOI: 10.1128/AAC.32.1.96

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Antimicrobial susceptibility of Pneumocystis carinii in culture.

Authors:  M S Bartlett; R Eichholtz; J W Smith
Journal:  Diagn Microbiol Infect Dis       Date:  1985-09       Impact factor: 2.803

2.  Pneumocystis carinii: growth variables and estimates in the A549 and WI-38 VA13 human cell lines.

Authors:  M T Cushion; J J Ruffolo; M J Linke; P D Walzer
Journal:  Exp Parasitol       Date:  1985-08       Impact factor: 2.011

3.  Treatment of Pneumocystis carinii pneumonitis. A comparative trial of sulfamethoxazole-trimethoprim v pentamidine in pediatric patients with cancer: report from the Children's Cancer Study Group.

Authors:  S E Siegel; L J Wolff; R L Baehner; D Hammond
Journal:  Am J Dis Child       Date:  1984-11

4.  Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.

Authors:  J A Kovacs; J W Hiemenz; A M Macher; D Stover; H W Murray; J Shelhamer; H C Lane; C Urmacher; C Honig; D L Longo
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

5.  Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome.

Authors:  F M Gordin; G L Simon; C B Wofsy; J Mills
Journal:  Ann Intern Med       Date:  1984-04       Impact factor: 25.391

6.  The treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.

Authors:  C B Small; C A Harris; G H Friedland; R S Klein
Journal:  Arch Intern Med       Date:  1985-05

7.  Efficacy of tetroxoprim/sulphadiazine in the treatment of Pneumocystis carinii pneumonitis in rats.

Authors:  Z Hussain; M L Carlson; I D Craig; R Lannigan
Journal:  J Antimicrob Chemother       Date:  1985-05       Impact factor: 5.790

8.  Effects of sulfonylurea compounds on Pneumocystis carinii.

Authors:  W T Hughes; B L Smith-McCain
Journal:  J Infect Dis       Date:  1986-05       Impact factor: 5.226

9.  Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; B L Smith
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro.

Authors:  M T Cushion; D Stanforth; M J Linke; P D Walzer
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

View more
  19 in total

Review 1.  Prophylaxis of Pneumocystis carinii pneumonia: too much of a good thing?

Authors:  R F Miller
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

2.  Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.

Authors:  D M Schmatz; M A Romancheck; L A Pittarelli; R E Schwartz; R A Fromtling; K H Nollstadt; F L Vanmiddlesworth; K E Wilson; M J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

3.  In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs.

Authors:  M Viora; A De Luca; A D'Ambrosio; A Antinori; E Ortona
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Fractionation of Pneumocystis carinii developmental stages by counterflow centrifugal elutriation and sequential filtrations.

Authors:  J A De Stefano; J M Foy; D W Sullivan; S M Dawes; M T Cushion; G F Babcock; R G Sleight; H van Halbeek; P D Walzer
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

5.  Furazolidone and nitrofurantoin in the treatment of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; C K Kim; J Foy; J L Zhang
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

6.  Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies.

Authors:  P D Walzer; J Runck; S Orr; J Foy; P Steele; M White
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

7.  Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.

Authors:  P D Walzer; J Foy; P Steele; M White
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

8.  Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia.

Authors:  W T Hughes; J Killmar
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; C K Kim; J Foy; M J Linke; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

10.  Development of a yeast assay for rapid screening of inhibitors of human-derived Pneumocystis carinii dihydrofolate reductase.

Authors:  Liang Ma; Qiuyao Jia; Joseph A Kovacs
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.